News

April 24, 2020April 24, 2020

Early Treatment Tied to Inactive Disease Within 1 Year, Canadian Registry Shows

News

Early treatment for juvenile idiopathic arthritis (JIA) is likely the reason for most children with JIA taking part in a Canadian patient registry having inactive disease within one year of diagnosis, a ... Read more

April 17, 2020April 17, 2020

Interleukin-33 Could Be Biomarker for JIA in Children, Study Indicates

News

Children with juvenile idiopathic arthritis (JIA) have high levels of a pro-inflammatory protein called interleukin-33 (IL-33) in their blood and the fluid around their joints compared to unaffected children, a new study reports. ... Read more

April 10, 2020April 10, 2020

Aristospan, JIA Treatment, Approved for Public Reimbursement in Canada

News

Aristospan (triamcinolone hexacetonide) — a treatment for juvenile idiopathic arthritis (JIA) and similar disorders — has been approved for public reimbursement in Canada, after the completion of price negotiations with the ... Read more

April 3, 2020April 3, 2020

Certain Vaccines in Children with Polyarticular JIA Maintain Effectiveness on Orencia, Study Finds

News

Young children with polyarticular juvenile idiopathic arthritis (pJIA) maintained effective vaccination against diphtheria and tetanus even after starting treatment with Orencia (abatecept) for up to two years, according to a ... Read more

April 2, 2020April 2, 2020

CHMP Recommends Enbrel Biosimilar Nepexto for Approval in Europe

News

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Nepexto, a biosimilar of Enbrel (etanercept), for the treatment of various inflammatory disorders including juvenile idiopathic arthritis. ... Read more

March 27, 2020March 31, 2020

Phase 3 Clinical Trial Tests Actemra for COVID-19 Pneumonia

News

The U.S. Food and Drug Administration (FDA) has approved starting a Phase 3 clinical trial testing Genentech‘s Actemra (tocilizumab) — a medicine approved for certain types of juvenile idiopathic arthritis ... Read more

March 20, 2020March 20, 2020

One-Fifth of JIA Patients Switch Out 1st Biological Therapy, UK Study Reports

News

About one-fifth of patients with juvenile idiopathic arthritis (JIA) under age 16 are switched to second biological therapies after first-line treatments fail or cause adverse effects, a large real-world study in ... Read more

March 17, 2020March 17, 2020

JIA Rheumatologist Wait Times Within Benchmarks, Canadian Study Finds

News

Children with juvenile idiopathic arthritis (JIA) generally saw rheumatologists within the recommended wait times, a Canadian single-center study found. Older patients waited longer, highlighting the need for better monitoring of ... Read more

March 13, 2020March 13, 2020

Study: Adding RoActemra to Methotrexate Not Generally Effective in Lessening Uveitis in JIA Patients

News

Adding RoActemra (tocilizumab) to methotrexate failed to show effectiveness in children and adolescents with treatment-resistant uveitis — inflammation of the eye — associated with juvenile idiopathic arthritis (JIA), a Phase 2 ... Read more

March 10, 2020March 10, 2020

Stopping Ilaris Post-remission Is Feasible in Systemic JIA Children, Study Finds

News

Treatment with Ilaris (canakinumab) can be discontinued without relapse in some children with systemic juvenile arthritis (sJIA), according to a recent small study. Sustained remission specifically appears to be more ... Read more